Mukonex (Ambroxol Hydrochloride)

Ambroxol stimulates surfactant production by type II pneumocytes and enhances ciliary beat frequency in the respiratory epithelium. These actions lower the viscosity of mucus, promote its clearance from the airways, and reduce cough reflex sensitivity, thereby improving breathing comfort.

The specific dose of Mukonex is determined by the prescribing healthcare professional based on the patient’s age, weight, renal and hepatic function, and the severity of the respiratory condition. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for Ambroxol Hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mukonex. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mukonex (Ambroxol) differs from agents such as N‑acetylcysteine by primarily stimulating surfactant secretion and ciliary activity, whereas N‑acetylcysteine acts mainly as a thiol‑donor that breaks disulfide bonds in mucus. Clinical choice depends on the patient’s condition, tolerability profile and physician preference.

Mukonex should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keeping the product in a dry, well‑ventilated area helps maintain its stability and potency.

Mukonex is taken orally, usually with a glass of water. The exact administration schedule—such as frequency and timing relative to meals—should follow the prescribing clinician’s directions to ensure optimal therapeutic effect.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, hepatotoxicity, and hematologic abnormalities like leukopenia. Patients should seek immediate medical attention if they experience symptoms such as rash, swelling, difficulty breathing, jaundice or unexplained bruising.

Mukonex is contraindicated in individuals with a known hypersensitivity to Ambroxol Hydrochloride or any of its excipients. It should also be avoided in patients with severe hepatic impairment unless specifically advised by a physician, and it is not recommended for use in children without appropriate medical supervision.